Cardiovascular
|
Cardiovascular diseases are the most common cause of death among people in the developed world.1 An important area of focus for improving treatment of heart disease is included in the Karolinska Development portfolio. This encompasses targeted measures against the kinds of inflammation that are often the basis for heart attacks and strokes, both acute and recurrent.
|
| Concept Development | Lead Discovery | Lead Optimization | Preclinical Development | Phase I | Phase II | Phase III | Launch | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Athera Biotechnologies AB (Annexin A5) |
|
|||||||||||||||
Athera Biotechnologies AB (PC-mAb) |
|
|||||||||||||||
Athera Biotechnologies ABAthera develops products for the risk assessment and treatment of cardiovascular disease related to inflammatory and immunological mechanisms. www.athera.se |
|
|
1) Source: WHO, The Global Burden of Disease: 2004 Update, 2008